Comparison of cytosol estrogen and progestin receptor status in malignant and benign tumors and tumor-like lesions of human ovary

Breed predispositions to canine digital neoplasms are well known. However, there is currently no statistical analysis identifying the least affected breeds. To this end, 2912 canine amputated digits submitted from 2014–2019 to the Laboklin GmbH & Co. KG for routine diagnostics were statistically analyzed. The study population consisted of 155 different breeds (most common: 634 Mongrels, 411 Schnauzers, 197 Labrador Retrievers, 93 Golden Retrievers). Non-neoplastic processes were present in 1246 (43%), tumor-like lesions in 138 (5%), and neoplasms in 1528 cases (52%). Benign tumors (n = 335) were characterized by 217 subungual keratoacanthomas, 36 histiocytomas, 35 plasmacytomas, 16 papillomas, 12 melanocytomas, 9 sebaceous gland tumors, 6 lipomas, and 4 bone tumors. Malignant neoplasms (n = 1193) included 758 squamous cell carcinomas (SCC), 196 malignant melanomas (MM), 76 soft tissue sarcomas, 52 mast cell tumors, 37 non-specified sarcomas, 29 anaplastic neoplasms, 24 carcinomas, 20 bone tumors, and 1 histiocytic sarcoma. Predisposed breeds for SCC included the Schnauzer (log OR = 2.61), Briard (log OR = 1.78), Rottweiler (log OR = 1.54), Poodle (log OR = 1.40), and Dachshund (log OR = 1.30). Jack Russell Terriers (log OR = −2.95) were significantly less affected by SCC than Mongrels. Acral MM were significantly more frequent in Rottweilers (log OR = 1.88) and Labrador Retrievers (log OR = 1.09). In contrast, Dachshunds (log OR = −2.17), Jack Russell Terriers (log OR = −1.88), and Rhodesian Ridgebacks (log OR = −1.88) were rarely affected. This contrasted with the well-known predisposition of Dachshunds and Rhodesian Ridgebacks to oral and cutaneous melanocytic neoplasms. Further studies are needed to explain the underlying reasons for breed predisposition or “resistance” to the development of specific acral tumors and/or other sites.

Download Full-text

“ROLE OF SPECTROSCOPY IN MAGNETIC RESONANCE IMAGING: A CLINICAL REVIEW”

10.36106/ijsr/3129141 ◽

2021 ◽

pp. 20-23

Author(s):

R. Adityan ◽

Sajith Selvaganesan

Keyword(s):

Magnetic Resonance ◽

High Sensitivity ◽

Benign Tumors ◽

Resonance Spectroscopy ◽

Clinical Implementation ◽

Cardiac Muscles ◽

Biochemical Evaluation ◽

Malignant And Benign Tumors ◽

Methylene Group

Magnetic Resonance Spectroscopy (MRS) is used in diagnostic imaging for disease metabolism evaluation. The H MRS is highly used because of the abundance, high sensitivity, etc. The various clinical implementation includes whole-brain MRS is used in measuring metabolites of different brain areas simultaneously. The breast MRS is used in malignant and benign tumors differentiation by the total choline compound. The prostate MRS is used to map the metabolites like citrate, choline, and creatinine. For spinal cord MRS, the myoinositol and N acetyl aspartate were 31 23 1 considered markers for various diseases. The MRS uses nuclei like P, Na, and H for metabolic and biochemical evaluation of cardiac muscles. The liver MRS spectrum has mainly methylene group of lipid, methyl groups of choline, and water. The MRS measures choline, creatinine, lactate, and lipid peaks in uterine leiomyoma and myometrium. Hence there are organ-specic metabolites used as a reference to map the metabolic process by using spectroscopy, making it one of the commonly preferred technique.

Download Full-text

A Comparison of the Changes in Carbohydrate, Fat, and Protein Metabolism Occurring with Malignant and Benign Tumors and the Impact of Nutritional Support

Cancer and Nutrition ◽

10.1007/978-1-4757-9561-5_3 ◽

1991 ◽

pp. 69-95 ◽

Cited By ~ 1

Author(s):

Antonio C. L. Campos ◽

Dan L. Waitzberg ◽

Michael M. Meguid

Keyword(s):

Protein Metabolism ◽

Nutritional Support ◽

Benign Tumors ◽

The Impact ◽

Malignant And Benign Tumors

Download Full-text

KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimickers

10.21203/rs.3.rs-29911/v1 ◽

2020 ◽

Author(s):

Lucen Jiang ◽

Jianghuan Liu ◽

Qingzhu Wei ◽

Yiyang Wang

Keyword(s):

Bone Tumor ◽

Bone Tumors ◽

Diagnostic Value ◽

Benign Tumors ◽

Malignant Bone Tumor ◽

Malignant Bone Tumors ◽

Potential Marker ◽

Tumors Of Bone ◽

Bone Sarcomas ◽

Malignant And Benign Tumors

Abstract Background Karyopherin α 2 (KPNA2), a member of the Karyopherin α family, has been observed in several cancers but lack substantial investigation in malignant bone tumors. The purpose of the current study was to evaluate KPNA2 expression level and its utility as a novel diagnostic biomarker in osteosarcomas and their malignant bone tumor mimickers, such as chondrosarcomas and Ewing sarcomas.Method We investigated the expression of KPNA2 protein by immunohistochemistry on paraffin embedded surgical specimens from 217 patients with malignant and benign tumors of bone, including 81 osteosarcomas, 42 chondrosarcomas, 9 Ewing sarcomas, 28 osteoid osteoma, 20 osteochondroma and 37 Chondroblastoma. Immunoreactivity was scored semi quantitatively based on stain extent and intensity.Results Seventy one of 81 (87.7%) osteosarcomas, zero of 42 (0%) chondrosarcomas and one of 9 (11.1%) Ewing sarcomas showed immunoreactivity for KPNA2. Negative KPNA2 expression was observed in all of benign bone tumors. Much more positive expression of KPNA2 was found in osteosarcomas as compared with chondrosarcomas and Ewing sarcomas. The sensitivity and specificity of KPNA2 immuno-expression for osteosarcoma was 87.7% and 100%, respectively. In several subtypes of osteosarcomas, immunohistochemical expression of KNA2 was more frequent in osteoblastic (94.5%), with 39 (70.9%) showing strong-intensity staining. KPNA2 positivity was observed in eleven of 13 (84.6%) chondroblastic, three of 6 (50%) fibroblastic, three of 4 (75%) telangiectatic and two of 3 (66.7%) giant cell-rich osteosarcoma. Stronger-intensity staining was observed in osteoblastic osteosarcoma.Conclusion KPNA2 is most frequently expressed in osteosarcomas, particularly in osteoblastic and chondroblastic tumors, but is rarely positive in chondrosarcomas and Ewing sarcomas. This feature may have diagnostic value since it is very useful for distinguishing between osteosarcomas and other bone sarcomas mimickers. This report supports KPNA2 as a novel marker for the diagnosis of osteosarcoma.

Download Full-text